Phase II study of gemcitabine (G) in combination with docetaxel (D) in advanced non-small-cell lung cancer (NSCLC) patients.: (Oncopaz and Hospitals Associated).

被引：0
|
作者：
García, C
Milla, A
Feliu, J
Lorenzo, A
Madroñal, C
Gili, F
Baena, JM
机构：
[1] H Gral Yague, Burgos, Spain
[2] Na Sa Pilar, Barcelona, Spain
[3] H La Paz, Madrid, Spain
[4] H Puerto Real, Cadiz, Spain
[5] Clin Corachan, Barcelona, Spain
[6] H Cruz Roja Hosp Llobregat, Barcelona, Spain
[7] H Puerta Mar, Cadiz, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
516P
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [1] Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    Rubinsak, J. R.
    Spigel, D. R.
    Hainsworth, J. D.
    Webb, C.
    Inhorn, R. C.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Vazquez, E. R.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study
    Pectasides, D
    Aspropotamitis, A
    Halikia, A
    Visvikis, A
    Antoniou, F
    Kalantaridou, A
    Karvounis, N
    Batzios, S
    Athanassiou, A
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3816 - 3821
  • [3] A phase II study of oxaliplatin and docetaxel in patients with advanced non-small-cell lung cancer (NSCLC)
    Raez, L
    Santos, E
    Rocha-Lima, C
    Roman, E
    Kumar, P
    Farfan, N
    Decesare, T
    Lopes, G
    Rosado, M
    Wu, J
    LUNG CANCER, 2005, 49 : S265 - S265
  • [4] Phase II study of docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Takigawa, N
    Segawa, Y
    Kishino, D
    Fujiwara, K
    Shinkai, T
    Watanabe, Y
    Tabata, M
    Kiura, K
    Ueoka, H
    Tanimoto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 776S - 776S
  • [5] Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer
    Shirai, T
    Hirose, T
    Noda, M
    Ando, K
    Lshida, H
    Hosaka, T
    Ozawa, T
    Okuda, K
    Ohnishi, T
    Ohmori, T
    Horichi, N
    Adachi, M
    LUNG CANCER, 2006, 52 (02) : 181 - 187
  • [6] Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
    Spigel, David R.
    Greco, F. Anthony
    Thompson, Dana S.
    Webb, Charles
    Rubinsak, James
    Inhorn, Roger C.
    Reeves, James, Jr.
    Vazquez, Elizabeth R.
    Lane, Cassie M.
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL LUNG CANCER, 2010, 11 (03) : 198 - 203
  • [7] Multi-institutional phase II study of docetaxel (D) and gemcitabine (G) as front-line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC).
    Amenedo, M
    Mel, JR
    Casal, J
    Rodriguez, MR
    Aparicio, LA
    Constenla, M
    Lopez, R
    Almanza, C
    Huarte, L
    ANNALS OF ONCOLOGY, 2000, 11 : 112 - 112
  • [8] Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
    Crino, L
    Scagliotti, G
    Marangolo, M
    Figoli, F
    Clerici, M
    DeMarinis, F
    Salvati, F
    Cruciani, G
    Dogliotti, L
    Pucci, F
    Paccagnella, A
    Adamo, V
    Altavilla, G
    Incoronato, P
    Trippetti, M
    Mosconi, AM
    Santucci, A
    Sorbolini, S
    Oliva, C
    Tonato, M
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 297 - 303
  • [9] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [10] Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy
    Chen, YM
    Perng, RP
    Lin, WC
    Wu, HW
    Tsai, CM
    Whang-Peng, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05): : 509 - 512
12345